Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer by Jin-Yuan Shih, Yung-Hung Luo, Gee-Chen Chang, John Wen-Cheng Chang, Chin-Chou Wang, Tsung-Ying Yang, Wei-Tse Fang, Wen-Yi Shau

Subjects: Get full text

Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status by Tomoyo Taketa, Takahito Nakamura

Subjects: Get full text

Lorlatinib After Alectinib-Induced Pneumonitis: A Case Report by James A. Fletcher, M.B.B.S., William J. Mullally, MBBCh BAO, Rahul Ladwa, MPhil, Kenneth J. O’Byrne, MD

Subjects: “…Lorlatinib…”
Get full text

Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion by Cesare Gridelli, Marcello Tiseo, Diego Luigi Cortinovis, Maria Rita Migliorino, Vito Barbieri, Paolo Bironzo, Alessandra Bearz, Ilaria Attili, Filippo de Marinis

Subjects: Get full text

Post-marketing safety of lorlatinib: a real-world study based on the FDA adverse event reporting system by Huqun Li, Chongshu Wang, Cuilian Guo

Subjects: “…lorlatinib…”
Get full text

The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic revi... by Luca Mastrantoni, Giulia Giordano, Emanuele Vita, Guido Horn, Jacopo Russo, Armando Orlandi, Gennaro Daniele, Diana Giannarelli, Giampaolo Tortora, Emilio Bria

Subjects: Get full text

Lorlatinib-Induced Pulmonary Embolism in a Patient With an ALK-Positive NSCLC by Ryo Toyozawa, MD, Naoki Haratake, MD, PhD, Gouji Toyokawa, MD, PhD, Taichi Matsubara, MD, PhD, Shinkichi Takamori, MD, PhD, Naoko Miura, MD, Masafumi Yamaguchi, MD, PhD, Mitsuhiro Takenoyama, MD, PhD, Takashi Seto, MD, PhD

Subjects: “…Lorlatinib…”
Get full text

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running? by Gianluca Spitaleri, Pamela Trillo Aliaga, Ilaria Attili, Ester Del Signore, Carla Corvaja, Chiara Corti, Edoardo Crimini, Antonio Passaro, Filippo de Marinis

Subjects: Get full text

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis by Ibiayi Dagogo-Jack, MD, Lesli A. Kiedrowski, MS, MPH, Rebecca S. Heist, MD, MPH, Jessica J. Lin, MD, Catherine B. Meador, MD, PhD, Elizabeth A. Krueger, NP, Andrew Do, BS, Jennifer Peterson, BS, Lecia V. Sequist, MD, MPH, Justin F. Gainor, MD, Jochen K. Lennerz, MD, PhD, Subba R. Digumarthy, MD

Subjects: Get full text

Successful Treatment of ALK-Positive Large-Cell Neuroendocrine Carcinoma of the Lung With Sequential ALK Inhibitors: A Case Report by Takayuki Kobayashi, MD, Yuji Uehara, MD, Kageaki Watanabe, MD, Tsunekazu Hishima, MD, Yukio Hosomi, MD

Subjects: Get full text

The underlying mechanisms of lorlatinib penetration across the blood‐brain barrier and the distribution characteristics of lorlatinib in the brain by Wei Chen, Dujia Jin, Yafei Shi, Yujun Zhang, Haiyan Zhou, Guohui Li

Subjects: Get full text

Inhibiting SCD expression by IGF1R during lorlatinib therapy sensitizes melanoma to ferroptosis by Furong Zeng, Lin Ye, Qian Zhou, Yi He, Yilei Zhang, Guangtong Deng, Xiang Chen, Hong Liu

Subjects: Get full text

Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC by Xiya Ma, Kun Zhang, Jing Xu, Hongjun Gao, Shaoxing Yang, Haifeng Qin, Hong Wang, Fang Gao, Xiaoqing Liu

Subjects: Get full text

Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis by Xu Feng, En-Shi Xu

Subjects: Get full text

ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance by Malinda Itchins, BMedSci, M.B.B.S., FRACP, PhD, Shirley Liang, BSc, Chris Brown, MBiostats, BSc, Tristan Barnes, BSc (Med), M.B.B.S., FRACP, Gavin Marx, BSc, M.B.B.S., FRACP, Venessa Chin, M.B.B.S., FRACP, PhD, Steven Kao, BHB, MBChB, PhD, FRACP, Po Yee Yip, MBChB, FRACP, PhD, Antony J. Mersiades, BMedSc, M.B.B.S., FRACP, MMed (Clin. Epi), Adnan Nagrial, M.B.B.S., FRACP, PhD, Victoria Bray, M.B.B.S., FRACP, PhD, Geoffrey Peters, BPharm, M.B.B.S., FRACP, Sagun Parakh, BSc, MBChB, FRACP, PhD, Kavita Garg, PhD, Bob T. Li, MD, PhD, MPH, Matthew McKay, PhD, Kenneth O'Byrne, M.B.B.S., FRACP, FRCPA, MD, Thomas John, M.B.B.S., FRACP, PhD, Anthony J. Gill, MD, FRCPA, Mark P. Molloy, PhD, Benjamin J. Solomon, M.B.B.S., FRACP, PhD, Nick Pavlakis, BSc, M.B.B.S., MMed (Clin. Epi), PhD, FRACP

Subjects: Get full text

Case report: Dissolving carotid plaque associated to Lorlatinib-related dyslipidemia by Lukas Mayer-Suess, Michael Knoflach, Michael Knoflach, Andreas Pircher, Stefan Kiechl, Stefan Kiechl, Christoph Schmidauer, Eva Hametner

Subjects: “…Lorlatinib…”
Get full text

Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib by Stefano Testa, Lynn Million, Teri Longacre, Nam Bui

Subjects: Get full text

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN by J. Guan, E. R. Tucker, H. Wan, D. Chand, L. S. Danielson, K. Ruuth, A. El Wakil, B. Witek, Y. Jamin, G. Umapathy, S. P. Robinson, T. W. Johnson, T. Smeal, T. Martinsson, L. Chesler, R. H. Palmer, B. Hallberg

Subjects: Get full text

Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report by Liang Dong, Jingwen Xia, Jing Zhang, Yuanyuan Zhang, Ning Zhu, Peng Zhang, Youzhi Zhang, Xiujuan Zhang, Shengqing Li

Subjects: Get full text

New findings on the incidence and management of CNS adverse reactions in ALK-positive NSCLC with lorlatinib treatment by Fanfan Chu, Wenxi Zhang, Hong Hu

Subjects: “…Lorlatinib…”
Get full text